Lee L - Search Results

1

Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis.

Steinman L, Fox E, Hartung HP, Alvarez E, Qian P, Wray S, Robertson D, Huang D, Selmaj K, Wynn D, Cutter G, Mok K, Hsu Y, Xu Y, Weiss MS, Bosco JA, Power SA, Lee L, Miskin HP, Cree BAC; ULTIMATE I and ULTIMATE II Investigators. Steinman L, et al. Among authors: lee l. N Engl J Med. 2022 Aug 25;387(8):704-714. doi: 10.1056/NEJMoa2201904. N Engl J Med. 2022. PMID: 36001711 Clinical Trial.

2

Improvement in Cognitive Function as Measured by NeuroTrax in Patients with Relapsing Multiple Sclerosis Treated with Natalizumab: A 2-Year Retrospective Analysis.

Gudesblatt M, Wissemann K, Zarif M, Bumstead B, Fafard L, Wilken J, Blitz K, Buhse M, Santra S, Hotermans C, Lee L. Gudesblatt M, et al. Among authors: lee l. CNS Drugs. 2018 Dec;32(12):1173-1181. doi: 10.1007/s40263-018-0553-1. CNS Drugs. 2018. PMID: 30143944 Free PMC article.

3

Outcomes of natalizumab treatment within 3 years of relapsing-remitting multiple sclerosis diagnosis: a prespecified 2-year interim analysis of STRIVE.

Perumal J, Fox RJ, Balabanov R, Balcer LJ, Galetta S, Makh S, Santra S, Hotermans C, Lee L. Perumal J, et al. Among authors: lee l. BMC Neurol. 2019 Jun 8;19(1):116. doi: 10.1186/s12883-019-1337-z. BMC Neurol. 2019. PMID: 31176355 Free PMC article. Clinical Trial.

4

Natalizumab in Early Relapsing-Remitting Multiple Sclerosis: A 4-Year, Open-Label Study.

Perumal J, Balabanov R, Su R, Chang R, Balcer L, Galetta S, Campagnolo DI, Avila R, Lee L, Rutledge D, Fox RJ. Perumal J, et al. Among authors: lee l. Adv Ther. 2021 Jul;38(7):3724-3742. doi: 10.1007/s12325-021-01722-w. Epub 2021 May 20. Adv Ther. 2021. PMID: 34014549 Free PMC article.

5

Characterizing the 'feel-good experience' in multiple sclerosis patients treated with natalizumab or other therapies.

Foley J, Berkovich R, Gudesblatt M, Luce E, Schneider B, de Moor C, Liao S, Lee L, Bodhinathan K, Avila R. Foley J, et al. Among authors: lee l. Neurodegener Dis Manag. 2023 Feb;13(1):23-34. doi: 10.2217/nmt-2022-0003. Epub 2022 Oct 26. Neurodegener Dis Manag. 2023. PMID: 36285716 Free article.

6

Correction to: Improvement in Cognitive Function as Measured by NeuroTrax in Patients with Relapsing Multiple Sclerosis Treated with Natalizumab: A 2-Year Retrospective Analysis.

Gudesblatt M, Wissemann K, Zarif M, Bumstead B, Fafard L, Wilken J, Blitz K, Buhse M, Santra S, Hotermans C, Lee L. Gudesblatt M, et al. Among authors: lee l. CNS Drugs. 2018 Dec;32(12):1183. doi: 10.1007/s40263-018-0574-9. CNS Drugs. 2018. PMID: 30244406 Free PMC article.

7

Correction to: Natalizumab in Early Relapsing-Remitting Multiple Sclerosis: A 4-Year, Open-Label Study.

Perumal J, Balabanov R, Su R, Chang R, Balcer L, Galetta S, Campagnolo DI, Avila R, Lee L, Rutledge D, Fox RJ. Perumal J, et al. Among authors: lee l. Adv Ther. 2021 Jul;38(7):3743-3744. doi: 10.1007/s12325-021-01815-6. Adv Ther. 2021. PMID: 34159559 Free PMC article. No abstract available.

8

The 5-year Tysabri global observational program in safety (TYGRIS) study confirms the long-term safety profile of natalizumab treatment in multiple sclerosis.

Foley J, Carrillo-Infante C, Smith J, Evans K, Ho PR, Lee L, Kasliwal R, Stangel M, Vermersch P, Hutchinson M, Marinelli F, Smirnakis K; TYGRIS investigators. Foley J, et al. Among authors: lee l. Mult Scler Relat Disord. 2020 Apr;39:101863. doi: 10.1016/j.msard.2019.101863. Epub 2019 Nov 21. Mult Scler Relat Disord. 2020. PMID: 31901758

9

RNA therapeutics in targeting G protein-coupled receptors: Recent advances and challenges.

Yuan W, Shi X, Lee LTO. Yuan W, et al. Among authors: lee lto. Mol Ther Nucleic Acids. 2024 Apr 24;35(2):102195. doi: 10.1016/j.omtn.2024.102195. eCollection 2024 Jun 11. Mol Ther Nucleic Acids. 2024. PMID: 38741614 Free PMC article. Review.

10

What hidden treasure resides beneath the waves?: Phytochemistry, pharmacological properties and uses of Halopteris scoparia (Linnaeus) Sauvageau 1904: An overview.

Aalilou Y, Moussa H, Lee LH, Bouyahya A, Zengin G, Faouzi MEA. Aalilou Y, et al. Among authors: lee lh. Fitoterapia. 2024 May 11:106016. doi: 10.1016/j.fitote.2024.106016. Online ahead of print. Fitoterapia. 2024. PMID: 38740345 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

9,986 results

Search Page